Phase 3 Trial of Relugolix for Advanced Prostate Cancer Completes Patient Enrollment

Phase 3 Trial of Relugolix for Advanced Prostate Cancer Completes Patient Enrollment
A Phase 3 trial evaluating Myovant Sciences’ relugolix as a treatment for advanced prostate cancer patients who are sensitive to androgen deprivation treatments has completed patient enrollment, the company announced. The randomized trial, called HERO (NCT03085095), is examining if relugolix is better than standard treatment leuprolide acetate (marketed under the brand names Eligard and Lupron) at lowering testosterone levels to castrate levels

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *